DeSantis group gives up large INBP stake; CDDS 2.0, LLC now over 5% (INBP)

Rhea-AI Filing Summary

Integrated BioPharma Inc. saw a long‑standing shareholder group led by the late Carl DeSantis, CD Financial, LLC and CDS Group Holdings, L.L.C. report that it no longer beneficially owns any common stock. The filing states the group’s holdings fell to 0 shares, or 0.0% of the class.

Following DeSantis’s death, all of the group’s shares were transferred on March 24, March 30 and April 15, 2026 to CDDS 2.0, LLC, a Florida company controlled by Damon DeSantis. As a result, CDDS 2.0, LLC directly, and Damon DeSantis indirectly, now beneficially own more than five percent of Integrated BioPharma’s common stock.

Key Figures

Current beneficial ownership: 0 shares Ownership percentage: 0.0% Cessation of beneficial ownership date: April 15, 2026 +2 more

5 metrics

Current beneficial ownership 0 shares Group’s common stock holdings after transfers

Ownership percentage 0.0% Percent of Integrated BioPharma common stock now held by the group

Cessation of beneficial ownership date April 15, 2026 Date group ceased to be beneficial owner of more than 5%

Transfer dates March 24, 2026; March 30, 2026; April 15, 2026 Dates all group shares were transferred to CDDS 2.0, LLC

New holder status More than 5% CDDS 2.0, LLC and Damon DeSantis beneficial ownership level

Key Terms

beneficial owner, Section 13 reporting status, dispositive power, Schedule 13D, +1 more

5 terms

beneficial owner financial

"the Reporting Persons ceased to be the beneficial owner of more than five percent"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

Section 13 reporting status regulatory

"the Reporting Persons ceased to be the beneficial owner of more than five percent ... and have exited Section 13 reporting status"

dispositive power financial

"Sole Dispositive Power 0.00 10 | Shared Dispositive Power 0.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

Schedule 13D regulatory

"Statement of Beneficial Ownership on , originally filed ... on March 28, 2003"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

Joint Filing Agreement regulatory

"99.1 Joint Filing Agreement, as required by Rule 13d-1 (k)"

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 4)

INTEGRATED BIOPHARMA INC

(Name of Issuer)

Common Stock, Par value $.002

(Title of Class of Securities)

45811V105

(CUSIP Number)

William Milmoe
109 SE 5th Avenue, Second Floor
Delray Beach, FL, 33483
561-278-1169

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

04/15/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 45811V105

1

Name of reporting person

DESANTIS CARL

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.0 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s): 45811V105

1

Name of reporting person

CD Financial, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

FLORIDA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.0 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 45811V105

1

Name of reporting person

CDS Group Holdings, L.L.C.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

FLORIDA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.0 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, Par value $.002
(b)	Name of Issuer: INTEGRATED BIOPHARMA INC
(c)	Address of Issuer's Principal Executive Offices: 225 LONG AVENUE, BUILDING 15, HILLSIDE, NEW JERSEY , 07205.
Item 2.	Identity and Background
(a)	This amendment No. 4 (this "Amendment") relates to the shares of common stock, par value $0.002 per share (the "Common Stock") of Integrated BioPharma, Inc., a Delaware corporation (the "Issuer"). This Amendment amends only the information previously reported with respect to Carl DeSantis, CD Financial, LLC, and CDS Group Holdings, L.L.C. (the "Reporting Persons") in the Statement of Beneficial Ownership on Schedule 13D, originally filed by Trade Investment Services, LLC, EVJ, LLC, EGK, LLC, CDS International Holdings, Inc., Robert B. Kay, E. Gerald Kay and Carl DeSantis with the Securities and Exchange Commission (the "Commission") on March 28, 2003, as amended by Amendment 1, filed with the Commission on July 22, 2003, Amendment No. 2, filed with the Commission on December 20, 2006, and Amendment No. 3, filed with the Commission on August 12, 2008. This Amendment is being filed to report that as of April 15, 2026, the Reporting Persons ceased to be the beneficial owner of more than five percent of the outstanding shares of the Issuer and have exited Section 13 reporting status. The Issuer's principal executive offices are located at 225 Long Avenue, Hillside, New Jersey 07205. The Names of the Reporting Persons are: i. CD Financial, LLC, a Florida limited liability company ("CD") ii. CDS Group Holdings, L.L.C., a Florida limited liability company ("CDS") iii. Carl DeSantis, a deceased individual ("DeSantis", and, together with CD and CDS, the "Group")
(b)	i. CD: 109 SE 5th Avenue Second Floor, Delray Beach, FL 33483 ii. CDS: 109 SE 5th Avenue Second Floor, Delray Beach, FL 33483 iii. DeSantis: C/O, Estate Representative, 109 SE 5th Avenue, Second Floor, Delray Beach, FL 33483
(c)	i. CD: N/A ii. CDS: N/A iii. DeSantis - deceased. The prior occupation of the Reporting Person was Chairman of CDS International Holdings, Inc.
(d)	During the last five years, no member of the Group has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e)	During the last five years, no member of the Group has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f)	i. CD: Florida ii. CDS: Florida iii. DeSantis - deceased. United States
Item 3.	Source and Amount of Funds or Other Consideration
	Not applicable. This Amendment reports the cessation of beneficial ownership of the Reporting Persons due to the death of DeSantis and the transfer described in Item 4.
Item 4.	Purpose of Transaction
	As a result of the death of DeSantis on August 10, 2023, all of the Group's shares of Common Stock of the Issuer were transferred to CDDS 2.0, LLC, a Florida limited liability Company, wholly owned by DeSantis's beneficiary, Damon DeSantis, on March 24, 2026, March 30, 2026 and April 15, 2026 (the "Transfer"). Following the final Transfer of shares of Common Stock, the Group ceased to be the beneficial owner of any shares of Common Stock of the Issuer. The Group, including the estate of DeSantis, has no present plans or proposals which relate to or would result in any of the matters set forth in subparagraphs (a) through (j) of Item 4 of Schedule 13D.
Item 5.	Interest in Securities of the Issuer
(a)	The Group beneficially owns 0 shares of Common Stock, representing 0.0% of the class of shares of Common Stock subject hereof.
(b)	The Group has no sole or shared voting or dispositive power with respect to the shares of Common Stock.
(c)	Except for the transactions described in Item 4, the Group has not effected any transaction in the shares of Common Stock subject hereof during the sixty (60) days prior to the date of this Amendment.
(d)	Immediately following the Transfer, CDDS 2.0, LLC owned more than five percent of the shares of Common Stock of the Issuer. CDDS 2.0, LLC is a Florida limited liability company controlled by Damon DeSantis. As a result, CDDS 2.0, LLC directly, and Damon DeSantis indirectly, beneficially own more than five percent of the shares of Common Stock of the Issuer.
(e)	The Group ceased to be a beneficial owner of the shares of Common Stock subject hereof on April 15, 2026.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	The Reporting Persons do not have any contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to any contracts, arrangements, understandings or relationships concerning the transfer or voting of such securities, finder?s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies.
Item 7.	Material to be Filed as Exhibits.
	99.1 Joint Filing Agreement, as required by Rule 13d-1 (k) under the Securities Exchange Act of 1934, as amended.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

DESANTIS CARL

Signature:	/s/ William Milmoe
Name/Title:	William Milmoe/Personal Representative
Date:	04/17/2026

CD Financial, LLC

Signature:	/s/ William Milmoe
Name/Title:	William Milmoe/President
Date:	04/17/2026

CDS Group Holdings, L.L.C.

Signature:	/s/ William Milmoe
Name/Title:	William Milmoe/Manager
Date:	04/17/2026

FAQ

What change in ownership does this Integrated BioPharma (INBP) filing report?

The filing reports that the DeSantis-led group now owns 0 shares of Integrated BioPharma common stock, or 0.0% of the class. Their exit from beneficial ownership status follows transfers of all shares to CDDS 2.0, LLC controlled by Damon DeSantis.

Who previously reported a significant stake in Integrated BioPharma (INBP)?

The reporting group consisted of CD Financial, LLC, CDS Group Holdings, L.L.C., and the late individual investor Carl DeSantis. Together, they had previously been beneficial owners of more than five percent of Integrated BioPharma’s common stock before fully transferring their position in 2026.

Who now holds more than 5% of Integrated BioPharma (INBP) according to this document?

Immediately after the transfers, CDDS 2.0, LLC owned more than five percent of Integrated BioPharma’s common stock. CDDS 2.0, LLC is controlled by Damon DeSantis, so he is described as indirectly beneficially owning more than five percent of the company’s common stock.

Why did the DeSantis group cease to be a beneficial owner of INBP shares?

The group’s beneficial ownership ended after Carl DeSantis’s death and subsequent transfers of all group-held shares. On March 24, March 30 and April 15, 2026, the shares were transferred to CDDS 2.0, LLC, leaving the group with 0 shares and 0.0% ownership.

When did the DeSantis group’s reporting obligation under Section 13 for INBP end?

The amendment states that as of April 15, 2026, the reporting persons ceased to be beneficial owners of more than five percent of Integrated BioPharma’s outstanding shares and exited Section 13 reporting status, reflecting completion of the final share transfer on that date.

Does the DeSantis group have any current plans affecting Integrated BioPharma (INBP)?

The filing states that the group, including the estate of Carl DeSantis, has no present plans or proposals relating to any of the actions listed in Item 4 subparagraphs (a) through (j), such as mergers, major asset sales, or other control-related transactions.